HK Stock abnormal| Kolonbiotech-B(06990) continued to rise nearly 10%, after a drop of more than 30% in the previous month. Over 0.1 billion shares will be released from restrictions today.

Koronbo Tai Biological-B (06990) has rebounded for two consecutive days and rose nearly 10% in the morning. Previously, the stock had fallen by nearly 30% in the past month. As of the press time, it rose 9.14% to HKD 155.2 with a turnover of HKD 0.232 billion.

Zhitong Finance23:26 ET

Hong Kong stocks rebounded again, with pharmaceutical stocks rising, and the industry's investment and financing are expected to hit bottom and rebound. The release of innovative drug policies has provided bullish signals.

According to the Zhongtong Finance APP, pharmaceutical stocks have risen again. As of press time, Kexing Biotech-B (06990) rose 9.07%, reporting HKD 155.1; Zai Lab (09688) rose 4.63%, reporting HKD 14.02; Genscript Biotech (01548) rose 4.59%, reporting HKD 10.02; and Innocare (09969) rose 4.57%, reporting HKD 5.03. On the news front, the US June CPI slowed down more than expected, pushing the probability of a rate cut in September to nearly 90%. Pacific Securities pointed out that as the Fed's rate hike cycle comes to an end in the future, liquidity is expected to gradually ease.

Zhitong Finance21:56 ET

HK stocks saw unusual movement as the biomedical sector rallied, boosted by bullish policies for innovative drugs. There are still multiple catalysts for the sector in the second half of the year.

According to the Wise Money APP, biopharmaceutical stocks rebounded collectively. As of the press release, Remegen (09995) rose by 8.06%, to HKD 14.74; Kexing Biotech-B (06990) rose by 7.46%, to HKD 142.6; Genscript Biotech (01548) rose by 5.08% to HKD 9.52, and Junshi Bio (01877) rose by 4.17% to HKD 13. News-wise, on July 5th, the State Council's executive meeting reviewed and approved the "Implementation Plan for Supporting the Development of Innovative Drugs throughout the Entire Chain." Previously, the National Medical Insurance Bureau released the "First Launch Price of New Marketed Chemical Drugs".

Zhitong FinanceJul 10 22:23 ET

Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).

Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.

Zhitong FinanceJul 8 20:58 ET

Sichuan Kelun-Biotech Biopharmaceutical Avails of 370 Million Yuan in Structured Deposit Programs

Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) availed of two structured deposit programs from the Bank of Communications (HKG:3328, SHA:601328) for a total of 370 million yuan as of Friday, accor

MT NewswiresJul 8 06:19 ET

Guosen Securities: Q2 performance under short-term pressure, 24H2 pharmaceutical industry is expected to reach bottom and rebound.

Since 2024, the pharmaceutical sector has been impacted by macroeconomic environment and policies both domestically and abroad, with both A-share and H-share pharmaceutical indices falling by more than 20%, and the number of stocks in the sector that have risen is no more than 10%.

Zhitong FinanceJul 8 03:29 ET